Affiliation: Karolinska Institutet
Carracedo M, Persson O, Saliba Gustafsson P, Artiach G, Ehrenborg E, Eriksson P, et al
. Upregulated Autophagy in Calcific Aortic Valve Stenosis Confers Protection of Valvular Interstitial Cells. Int J Mol Sci. 2019;20: pubmed publisher
..In conclusion, our data suggests that autophagy is upregulated in the calcified tissue of CAVS, serving as a compensatory and pro-survival mechanism. ..
Bäck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des. 2009;15:3116-32 pubmed
..Several inhibitors of the 5-lipoxygenase pathway are now evaluated in clinical trials of patients with cardiovascular disease. ..
Laguna Fernandez A, Checa A, Carracedo M, Artiach G, Petri M, Baumgartner R, et al
. ERV1/ChemR23 Signaling Protects from Atherosclerosis by Modifying oxLDL Uptake and Phagocytosis in Macrophages. Circulation. 2018;: pubmed publisher
..In conclusion, ERV1/ChemR23 signaling may represent a previously unrecognized therapeutic pathway to reduce atherosclerotic cardiovascular disease. ..
Gautier Veyret E, Bäck M, Arnaud C, Belaidi E, Tamisier R, Levy P, et al
. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome. Pharmacol Res. 2018;134:311-319 pubmed publisher
..In the era of personalized medicine, U-LTE4 may be a useful biomarker to identify OSA patients for whom CysLT1 blockade could represent a new therapeutic avenue for reducing cardiovascular risk. ..
Ketelhuth D, Hermansson A, Hlawaty H, Letourneur D, Yan Z, BÃ¤ck M. The leukotriene B4 receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoE-/- mice. Prostaglandins Other Lipid Mediat. 2015;121:105-9 pubmed publisher
..Taken together, these results suggest a therapeutic value of BLT receptor antagonism in atherosclerosis. ..
Bäck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928-33 pubmed publisher
..79-1.11). Whereas safety measures appear to have limited serious cardiovascular consequences of COX-2 inhibitors, the risk of developing atrial fibrillation may have been overlooked and may necessitate consideration and precautions. ..
Bäck M. Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep. 2008;10:244-51 pubmed
..Taken together, the leukotriene pathway may represent a putative therapeutic target in the treatment of atherosclerotic vessel disease. ..
Bäck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23:41-8 pubmed publisher
..Both leukotriene synthesis inhibitors and leukotriene receptor antagonists have been suggested to induce beneficial effects at different stages of the atherosclerosis process. ..
Bäck M, Dahlen S, Drazen J, Evans J, Serhan C, Shimizu T, et al
. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011;63:539-84 pubmed publisher
..The aim of this review is to provide an update on the pharmacology, expression patterns, and pathophysiological roles of the leukotriene receptors as well as the therapeutic developments in this area of research. ..